- Page 1 and 2: Managing Challenges Solvay Global A
- Page 3 and 4: Key fi gures - Solvay Group Financi
- Page 5 and 6: February 1 Caprolactones Solvay con
- Page 7 and 8: Apart from increasing our competiti
- Page 9 and 10: and optional overtime and taking of
- Page 11 and 12: ... and Long-Term Value Creation Th
- Page 13 and 14: and using it without limits, the pi
- Page 15 and 16: Chemicals Sales: EUR 3.1 billion -
- Page 17 and 18: 2008 : operating result down 19% on
- Page 19 and 20: EUR million 2007 2008 2008/2007 GRO
- Page 21 and 22: Balance sheet Total Equity stood at
- Page 23 and 24: Current profi t before taxes amount
- Page 25 and 26: Robot in Weesp. This 384 wells plat
- Page 27 and 28: Key fi gures [EUR million] 2006 200
- Page 29 and 30: Flagship Products in 2008 Therapeut
- Page 31 and 32: Sales of less important products In
- Page 33 and 34: Sodium bicarbonate. Sodium bicarbon
- Page 35 and 36: Key fi gures [EUR million] 2006 200
- Page 37 and 38: natural resources and limit waste d
- Page 39 and 40: The Organic cluster: Molecular Solu
- Page 41 and 42: Solvay specialty polymers The outst
- Page 43 and 44: Key fi gures [EUR million] 2006 200
- Page 45 and 46: Technological leadership through Re
- Page 47: production capacities have been inc
- Page 51 and 52: future) reacts with atmospheric oxy
- Page 53 and 54: Increasing cultural diversity. Solv
- Page 55 and 56: New career management process In 20
- Page 57 and 58: The 5x5 Matrix The 5x5 Matrix is th
- Page 59 and 60: Investors: responding to growing in
- Page 61 and 62: Financial Statements The following
- Page 63 and 64: Consolidated balance sheet EUR Mill
- Page 65 and 66: Minority interests The increase in
- Page 67 and 68: • IFRIC 15 Agreements for the con
- Page 69 and 70: 9. Research and Development costs R
- Page 71 and 72: Key assumptions & key sources of es
- Page 73 and 74: General description of the segments
- Page 75 and 76: Information per primary segment for
- Page 77 and 78: For the Pharmaceuticals Sector, whi
- Page 79 and 80: - Current tax represents the tax pa
- Page 81 and 82: Other information All the Group’s
- Page 83 and 84: The acquisitions in 2008 consist ma
- Page 85 and 86: Alexandria Sodium Carbonate On 17 O
- Page 87 and 88: (20) Capital increase / redemption
- Page 89 and 90: Consolidated balance sheet (22) Int
- Page 91 and 92: (24) Tangible assets (including fi
- Page 93 and 94: (26) Other investments EUR million
- Page 95 and 96: (29) Provisions EUR Million Employe
- Page 97 and 98: The amounts recorded in the balance
- Page 99 and 100:
Actuarial assumptions used in deter
- Page 101 and 102:
- the risks attached to ongoing lit
- Page 103 and 104:
Fair value of fi nancial debts For
- Page 105 and 106:
) Balance sheet risk The Group’s
- Page 107 and 108:
Financial instruments IAS 39 defi n
- Page 109 and 110:
(32) Assets held for sale and liabi
- Page 111 and 112:
Management of Risks Acting responsi
- Page 113 and 114:
In reference to Raw Materials, in a
- Page 115 and 116:
Since 2007 a compliance organizatio
- Page 117 and 118:
Participation in venture capital fu
- Page 119 and 120:
Compensation report 1. Description
- Page 121 and 122:
affi liated to the Pension Regulati
- Page 123 and 124:
Companies leaving the Group Country
- Page 125 and 126:
SolVin France SA, Paris 75 Pl Vival
- Page 127 and 128:
Solvay Soda Ash Joint Venture, Hous
- Page 129 and 130:
FINLAND Pipelife Finland OY, Oulu 5
- Page 131 and 132:
Summary fi nancial statements of So
- Page 133 and 134:
STATUTORY AUDITOR’S REPORT To the
- Page 135 and 136:
Report on the application of the Co
- Page 137 and 138:
Introduction This report presents t
- Page 139 and 140:
The Board of Directors noted their
- Page 141 and 142:
notice of the meeting by mail at th
- Page 143 and 144:
Year of birth Year of 1st appointme
- Page 145 and 146:
eing a non-executive director of a
- Page 147 and 148:
4.5.2. The Audit Committee At Janua
- Page 149 and 150:
corresponding to the decision or re
- Page 151 and 152:
which remained valid for the 2008 f
- Page 153 and 154:
Manager, a member of the Executive
- Page 155 and 156:
EUR The Solvay share compared with
- Page 157 and 158:
ANNEX 1 Audit Committee Mission Sta
- Page 159 and 160:
during the 30 days preceding the st
- Page 161 and 162:
Executive Committee 1 | Christian J
- Page 163 and 164:
ABAF: Belgian Financial Analysts As
- Page 165 and 166:
Shareholders’ Diary - Tuesday May